Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11194093 | 0.90 | DNM1 (0.43) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL11198711 | 0.90 | DNM1 (0.43) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL9579090 | 0.84 | TSHR (0.38) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL25735578 | 0.82 | DNM1 (0.57) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL19554001 | 0.82 | DNM1 (0.38) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL28758154 | 0.81 | DNM1 (0.55) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL7770093 | 0.80 | — | — | |
| SCHEMBL20212033 | 0.79 | TSHR (0.46) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL27934764 | 0.79 | DNM1 (0.60) | DNM1CA12CA1CA9CA2 | |
| SCHEMBL27623778 | 0.79 | DNM1 (0.60) | DNM1CA12CA1CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198218-B2 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-06-12 | — | — | US | disclosed |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | AADAC, ABCG2, RICTOR | DNM1 1859/4885CA12 2698/4885CA1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.